Information Provided By:
Fly News Breaks for March 28, 2017
CARA
Mar 28, 2017 | 08:53 EDT
Laidlaw analyst Jim Molloy raised Cara Therapeutics' price target to $35 from $20 saying this morning's Phase 2b trial data of IV CR845 for for moderate to severe pruritus in dialysis patients is a "huge positive." Molly tells investors CR845 is potentially a "blockbuster" indication, which is also being tested for post-operative pain and osteoarthritis of the knee pain, with data expected on those indications in 2H 2017. Molloy has a Buy rating on Cara shares.
News For CARA;CARA From the Last 2 Days
There are no results for your query CARA;CARA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.